Conclusions

- It showed better clinical outcomes in the gemcitabine plus nab-paclitaxel group in PFS.
- The nab-paclitaxel can be an effective second-line chemotherapy in gemcitabine resistant patients.

No conflict of interest.

**CPC-127** SEVERAL TYPES OF PROTEINURIA AND ASSOCIATED FACTORS AMONG HIV-INFECTED ADULTS IN THE HAART ERA

doi:10.1136/ehjpharm-2013-000276.584

1E Guille, 2C Psomas, 3M Chaton, 4A Couril, 5J Reynes. *University Hospital of Montpellier, Pharmacy, Montpellier Cedex 5, France; 1University Hospital of Montpellier, Department of Infectious Diseases, Montpellier Cedex 5, France; 2University Hospital of Montpellier, Biochemistry, Montpellier Cedex 5, France; 4University Hospital of Montpellier, IRD Inst Res Dev, Montpellier Cedex 5, France*

**Background** HIV-infected individuals have an increased risk of chronic kidney disease.

**Purpose** To evaluate the prevalence of different types of proteinuria and associated factors in a HIV-infected population with a high percentage (92%) of Caucasian origin.

**Materials and Methods** Cross-sectional study of all HIV-infected adults seen at the Montpellier University Hospital HIV outpatients unit over 6 months. Demographics, treatment history, comorbidities and laboratory data were collected from an electronic database and manual review chart. Spot urine protein to creatinine (uPCR) and albumin to creatinine (uACR) ratios, estimated glomerular filtration rate using the MDRD equation (eGFR) were assessed. Three types of proteinuria were defined: tubular proteinuria (uPCR > 200 mg/g and albuminuria/proteinuria <0.5), glomerular proteinuria (uPCR > 200 mg/g and albuminuria/proteinuria > 0.5), microalbuminuria (uPCR < 200 mg/g and uACR 30–300 mg/g). Multivariate logistic regression was used to identify independent factors of proteinuria for patients with eGFR > 60 mL/min/1.73 m².

**Results** Characteristics for 1210 patients were: median age 48 years, 26% women, 71% black, 93% on HAART, 54% on tenofovir, median CD4 cell count 488 cell/µl, 73% with HIV viral load <20 copies/ml, 7.8% hypertensive, 3.4% diabetic, 18.2% HCV positive, 73% with HIV viral load <20 copies/ml, 7.8% hypertensive, 3.4% diabetic, 18.2% HCV positive, 73% with HIV viral load <20 copies/ml, 7.8% hypertensive, 3.4% diabetic, 18.2% HCV positive, 73% with HIV viral load <20 copies/ml, 7.8% hypertensive, 3.4% diabetic, 18.2% HCV positive.

**Conclusions** The prevalence of proteinuria or microalbuminuria was 18.1% in this predominantly white, cART (current antiretroviral therapy)-experienced cohort. Measuring uPCR and albuminuria may assist in the diagnosis of early renal disease.

**Abstract CPC-127 Table 1**

<table>
<thead>
<tr>
<th>Patients</th>
<th>No Proteinuria uPCR &lt; 200 mg/g</th>
<th>Proteinuria uPCR &gt; 200 mg/g</th>
</tr>
</thead>
<tbody>
<tr>
<td>DFG &lt; 60</td>
<td>86.3% (997/1156)</td>
<td>13.7% (159/1156)</td>
</tr>
<tr>
<td>DF G &gt; 60</td>
<td>4.4% (51/1156)</td>
<td>9.6% (111/1156)</td>
</tr>
</tbody>
</table>

No conflict of interest.

**CPC-128** START SMART THEN FOCUS – A SURVEY OF ANT IMICROBIAL STEWARDSHIP GUIDELINES IMPLEMENTATION IN ENGLAND

doi:10.1136/ehjpharm-2013-000276.585

1P Howard, 2J Cooke, 3C Fry, 4C McNulty, 5H Khoda, 6S Wellstead, 7U Stockley, 8H Loveday, 9L Brown. *Leeds Teaching Hospitals NHS Trust, Pharmacy, Leeds, UK; 1University of Manchester, Pharmacy, Manchester, UK; 2Department of Health, Infectious Diseases and Blood Policy, London, UK; 3Health Protection Agency, Primary Care Unit, Gloucester, UK; 4Health Protection Agency, HCAI and AMR Programme Team, London, UK; 5Worcester Acute Hospitals NHS Trust, Microbiology, Worcester, UK; 6University of West London, College of Nursing Midwifery and Healthcare, London, UK*

**Background** Start Smart then Focus Antimicrobial Stewardship (AMS) guidance for England was launched in November 2011 on European Antimicrobial Awareness Day.

**Purpose** To identify the extent of guideline implementation, whether the guidelines had improved AMS, and to collect examples of good practice.

**Materials and Methods** A web-based survey was developed using SurveyMonkey software, piloted, and then distributed through the microbiology, infectious diseases and pharmacy networks in July 2012.

**Results** There were 74 responses (44%) to the Start Smart then Focus (SSTF) guidance by September. SSTF was rated excellent or good by 65% for making AMS a Trust priority; by 57% for improving their AMS infrastructure; by 51% for improving prescribing practise; by 57% for improving audit and by 31% for improved usage reporting. Only 12% to 22% thought it was poor or less than satisfactory for the same criteria.

A formal review of SSTF has been done by 41%, with 17% planning to do so. 86% had done an informal review. 52% had developed an action plan.

The main barriers to implementation were a lack of microbiology/ infectious diseases time, then pharmacist time. An established AMS group, an enthusiastic pharmacist or microbiologist, or adequate time, were the main facilitators.

Putting the indication and duration or a review date on inpatient antimicrobial prescriptions were in place prior to SSTF in 67% and 75% of centres respectively. Since SSTF a further 9% have started and another 13% and 10% plan to implement these suggestions by April 2013.

Additional antimicrobial ward rounds have started or are planned since SSTF in medical wards by 20%, surgical wards by 19% and paediatrics by 10% of centres.

**Conclusions** The Start Smart then Focus Antimicrobial Stewardship guidance has helped to further implement AMS in England.

No conflict of interest.

**CPC-129** STUDY OF A PHARMACISTS CONTRIBUTION TO MEDICINES RECONCILIATION IN CRITICALLY ILL PATIENTS

doi:10.1136/ehjpharm-2013-000276.586

1C Lopez Martin, 2I Aquerreta, 3I Aidoate, 4V Faus. *Hospital Costa del Sol, Pharmacy, Marbella, Spain; 3Clinica Universidad de Navarra, Pharmacy, Pamplona, Spain*

**Background** Medicines reconciliation in intensive care units (ICU) is essential in preventing medicines errors. Medicines reconciliation errors have been found to occur mainly in the transition of care.

**Purpose** To develop and evaluate a medicines reconciliation programme in critically ill patients.

**Materials and Methods** Prospective study. Discrepancies between chronic treatment and treatment prescribed by the hospital physician in patients admitted to the ICU were analysed. Medicines histories were obtained from the medical history and patient interview. If discrepancies were found, the ICU physician was contacted.